Study guide

12.2 Insulin & Noninsulin Glycemic Agents

APMLE Part I Basic Sciences Podiatry

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Lower Extremity Osteology

1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics

2 Chapter 2: Lower Extremity Arthrology & Ligaments

2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics

3 Chapter 3: Lower Extremity Myology & Compartments

3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations

4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy

4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces

5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods

5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines

6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology

6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

7 Chapter 7: General & Cellular Pathology

7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors

8 Chapter 8: Systemic & Podiatric Pathology

8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation

9 Chapter 9: Organ-System Pathology

9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology

10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology

10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

11 Chapter 11: Antimicrobial & Podiatric Therapeutics

11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology

12 Chapter 12: Systemic Pharmacology

12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy

13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways

14 Chapter 14: Histology, Integument, Embryology & Genetics

14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging

15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology

15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics

16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology

17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling

17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction

18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals

12.2 Insulin & Noninsulin Glycemic Agents

Key Takeaways Explain This Topic AI

Rapid-acting insulin analogs (lispro, aspart, glulisine) start working within about 15 minutes, regular insulin within 30–60 minutes, NPH peaks at about 4–10 hours, and glargine and degludec provide basal coverage without a pronounced peak.

Metformin lowers hepatic gluconeogenesis without causing hypoglycemia on its own; it is contraindicated below an eGFR of 30 mL/min/1.73 m² and long-term use can cause vitamin B12 deficiency that worsens neuropathy.

SGLT2 inhibitors cause glycosuria and can precipitate euglycemic ketoacidosis around surgery, so they are held about 3 days beforehand (4 days for ertugliflozin); they also cause genital mycotic infections and carry a Fournier gangrene warning.

GLP-1 receptor agonists and tirzepatide slow gastric emptying, promote weight loss and carry a boxed warning for thyroid C-cell tumors; DPP-4 inhibitors have warnings for severe arthralgia and bullous pemphigoid.

Sulfonylureas close beta-cell K-ATP channels and cause hypoglycemia; pioglitazone causes edema, can worsen heart failure and increases distal fracture risk, including in the foot.

Last updated: October 2026

12.2 Insulin & Noninsulin Glycemic Agents

The pharmacology outline lists glycemic agents : insulin and the oral, inhaled and injected hypoglycemic agents. Most patients with diabetic foot disease take several of these drugs. Their adverse effects (hypoglycemia, ketoacidosis, edema, fractures, B12 deficiency) and perioperative handling come up often in podiatric practice. The physiology of insulin secretion is in 16.3 and the second-messenger pathways in 17.4.

Insulin

  • Category Agents Onset Peak Duration
  • Rapid-acting Lispro, aspart, glulisine About 15 minutes 1–2 hours 3–5 hours
  • Short-acting Regular insulin 30–60 minutes 2–4 hours 5–8 hours
  • Intermediate NPH 1–2 hours 4–10 hours 10–18 hours
  • Long-acting Glargine 1–2 hours Minimal peak About 24 hours
  • Ultra-long-acting Degludec 1–2 hours Minimal peak More than 40 hours
  • Inhaled Technosphere insulin About 12 minutes About 1 hour 2–3 hours

Durations vary with dose and site. Inhaled insulin is rapid-acting and contraindicated in chronic lung disease (asthma, COPD) because it can cause acute bronchospasm; spirometry is required before starting it.

Mechanism. Insulin binds a receptor tyrosine kinase, which signals through IRS-1 and PI3K/Akt to move GLUT4 to muscle and fat membranes. It also stimulates glycogen, fat and protein synthesis and drives potassium into cells.

Adverse effects:

  • Hypoglycemia is the most important, more likely with renal impairment, missed meals and exercise
  • Weight gain
  • Lipohypertrophy at overused injection sites
  • Hypokalemia (which is why insulin is part of hyperkalemia treatment)

Hypoglycemia treatment. A conscious patient takes about 15 g of fast-acting carbohydrate and rechecks in 15 minutes. Severe hypoglycemia is treated with IV dextrose or with intramuscular, subcutaneous or intranasal glucagon . Patients on beta-blockers may have blunted warning symptoms, and sweating (sympathetic cholinergic) is often the remaining clue (10.3).

Noninsulin Agents

Class Examples Mechanism Key adverse effects and podiatric relevance

Biguanide Metformin Activates AMPK; decreases hepatic gluconeogenesis ; improves insulin sensitivity GI upset; rare lactic acidosis ; no hypoglycemia alone; vitamin B12 deficiency that can worsen neuropathy; contraindicated below an eGFR of 30, not started at an eGFR of 30–45

Sulfonylureas Glipizide, glimepiride, glyburide Close beta-cell K-ATP channels , causing depolarization, Ca2+ entry and insulin release Hypoglycemia (worst with glyburide in older or CKD patients), weight gain; overdose treated with dextrose plus octreotide

Meglitinides Repaglinide, nateglinide Same K-ATP target, short acting Hypoglycemia with skipped meals

Thiazolidinedione Pioglitazone PPAR-gamma agonist; increases insulin sensitivity Fluid retention and heart failure (boxed warning), weight gain, fractures (distal limbs, including the foot) , possible bladder cancer risk

DPP-4 inhibitors Sitagliptin, linagliptin, saxagliptin Prevent breakdown of endogenous GLP-1 and GIP Weight-neutral; severe arthralgia and bullous pemphigoid warnings; pancreatitis; saxagliptin heart failure signal

GLP-1 receptor agonists Semaglutide, dulaglutide, liraglutide, exenatide Glucose-dependent insulin release, glucagon suppression, slowed gastric emptying , satiety Nausea, vomiting, weight loss, pancreatitis, gallbladder disease, boxed warning for thyroid C-cell tumors (avoid with medullary thyroid carcinoma or MEN2); some agents have proven cardiovascular benefit

Dual GIP/GLP-1 agonist Tirzepatide Agonist at both incretin receptors Similar to GLP-1 receptor agonists with greater weight loss

SGLT2 inhibitors Empagliflozin, dapagliflozin, canagliflozin, ertugliflozin Block proximal tubule sodium-glucose cotransporter 2 , causing glycosuria Genital mycotic infections , UTI, volume depletion, euglycemic DKA , Fournier gangrene warning; canagliflozin carries a lower-limb amputation warning; proven heart failure and kidney benefit

Alpha-glucosidase inhibitors Acarbose, miglitol Delay intestinal carbohydrate digestion Flatulence; treat hypoglycemia with glucose , not sucrose

Amylin analog Pramlintide Slows gastric emptying, suppresses glucagon Hypoglycemia when combined with insulin

Choosing therapy. Current diabetes standards emphasize lifestyle measures and metformin for many patients. They recommend an SGLT2 inhibitor or GLP-1 receptor agonist with proven benefit for people with atherosclerotic cardiovascular disease, heart failure or CKD, regardless of HbA1c. Hypoglycemia risk, weight effects, cost and comorbidities guide the rest.

Perioperative Management in Foot and Ankle Surgery

SGLT2 inhibitors: hold 3 days before scheduled surgery ( 4 days for ertugliflozin ) to reduce euglycemic DKA risk. Check ketones if the patient is unwell even when glucose is near normal.

Metformin: commonly held on the day of surgery; hold around iodinated contrast in patients with reduced renal function, and restart when eating and renal function is stable.

Sulfonylureas: hold on the morning of surgery to avoid fasting hypoglycemia.

Basal insulin: usually continued at a reduced dose (often about 75–80%) the evening before or morning of surgery; hold prandial insulin while fasting.

GLP-1 receptor agonists: slowed gastric emptying raises aspiration concern, so follow the current anesthesia guidance on holding doses or using a liquid diet beforehand.

Glucose targets: perioperative glucose of about 100–180 mg/dL is a common target. Hyperglycemia impairs neutrophil function and raises surgical site infection and nonunion risk.

Glucose and Wound Healing

Chronic hyperglycemia glycates collagen, impairs leukocyte chemotaxis and phagocytosis, and promotes microangiopathy (8.1). Improving glycemic control around surgery and during diabetic foot ulcer treatment supports healing, but aggressive lowering that causes hypoglycemia is also harmful, particularly in older adults.